Literature DB >> 24938448

The association between pulmonary function impairment and colon inflammation in ulcerative colitis patients: A scientific basis for exterior-interior correlation between lung and large intestine.

Jian-Yun Wang1, Xin-Yue Wang2, Hua-Yang Wu3, Hui-Yi Sun4, Da-Ming Liu4, Wen Zhang4, Chen-Xi Jin5, Shuo-Ren Wang6.   

Abstract

OBJECTIVE: To investigated the involvement of pulmonary function impairment in ulcerative colitis (UC), to explore a scientific basis for the Chinese medicine (CM) theory of exterior-interior correlation between Lung (Fei) and Large intestine (Dachang).
METHODS: Totally 120 patients with a diagnosis of UC were recruited and the demographics, clinical data, and blood samples were collected. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) concentrations were measured. Every patient accepted pulmonary function test and took chest radiograph (CXR).>
RESULTS: Pulmonary function abnormalities were present in 72 of 120 patients. The median (interquartile range) vital capacity (VC), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), carbon monoxide diffusion capacity (DLCO) of lung, total lung capacity (TLC) and functional residual volume (FRV) were decreased in distal UC and pancolitis compared with ulcerative prochitis (P <0.0005). Male patients had increased VC, FEV1/FVC, and residual volume (RV)/TLC compared with female (P <0.0005), but decreased DLCO and carbon monoxide iffusion capacity (KCO) of lung/alveolar ventilation (P <0.0005). Age was strongly correlated with RV (Spearman rank correlation coefficient (rs)=-0.57,P <0.0001), and RV/TLC (rs=0.48,P<0.0001). Age was also correlated with FEV1/FVC (rs=-0.29, P=0.001), forced expiratory flow in 75% vital capacity (FEF75%, rs=-0.20, P=0.03), DLCO (rs=-0.21, P=0.02), TLC (rs=-0.25, P=0.006), and FRV (rs=-0.28, P=0.002). The course of disease was correlated with FEF75% (rs=-0.18, P=0.049) and KCO (rs=-0.19, P=0.036). Chest radiograph abnormalities were presented in 38 of 120. Pulmonary symptoms were presented in 10 of 120. Other extraintestinal complications were presented in 21 of 120.
CONCLUSIONS: Pulmonary function impairment was more frequently than other extraintestinal complications in UC patients, which may be affected by sex, age, extent and course of disease. These results may be a scientific basis for the theory of exterior-interior correlation between Lung and Large intestine.

Entities:  

Keywords:  Chinese medicine; exterior-interior relationship between Lung and the Large intestine; pulmonary function impairment; ulcerative colitis

Mesh:

Year:  2014        PMID: 24938448     DOI: 10.1007/s11655-014-1842-2

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  33 in total

1.  Peripheral arthritis in the course of inflammatory bowel diseases.

Authors:  Ilhami Yüksel; Hilmi Ataseven; Omer Başar; Seyfettin Köklü; Ibrahim Ertuğrul; Aysel Ulker; Ulkü Dağlı; Nurgül Saşmaz
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

2.  Changes in pulmonary function in patients with ulcerative colitis.

Authors:  Aliaë A R Mohamed-Hussein; Nadia A S Mohamed; Mohamed-Eltaher A R Ibrahim
Journal:  Respir Med       Date:  2006-10-17       Impact factor: 3.415

3.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

4.  Inflammatory bowel disease and asthma: a population-based, case-control study.

Authors:  Yilma A Fenta; Natalia Tello; Ji A Jung; Sang-Hwa Urm; Edward V Loftus; Barbara P Yawn; Xujian Li; Young J Juhn
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

5.  The prevalence of ocular involvement in patients with inflammatory bowel disease.

Authors:  Safiye Yilmaz; Ebru Aydemir; Ahmet Maden; Belkis Unsal
Journal:  Int J Colorectal Dis       Date:  2007-01-30       Impact factor: 2.571

Review 6.  Role of eosinophils in inflammatory bowel and gastrointestinal diseases.

Authors:  Samantha A Woodruff; Joanne C Masterson; Sophie Fillon; Zachary D Robinson; Glenn T Furuta
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-06       Impact factor: 2.839

7.  Pulmonary involvement in inflammatory bowel disease.

Authors:  Aydin Yilmaz; Nilgün Yilmaz Demirci; Derya Hoşgün; Enver Uner; Yurdanur Erdoğan; Atila Gökçek; Atalay Cağlar
Journal:  World J Gastroenterol       Date:  2010-10-21       Impact factor: 5.742

8.  Value of fractional exhaled nitric oxide (FE NO) for the diagnosis of pulmonary involvement due to inflammatory bowel disease.

Authors:  Ezgi Ozyilmaz; Beytullah Yildirim; Gonca Erbas; Serpil Akten; I Kivilcim Oguzulgen; Bilge Tunc; Candan Tuncer; Haluk Turktas
Journal:  Inflamm Bowel Dis       Date:  2010-04       Impact factor: 5.325

Review 9.  Dermatological signs during inflammatory bowel diseases.

Authors:  C Feliciani; C De Simone; P Amerio
Journal:  Eur Rev Med Pharmacol Sci       Date:  2009-03       Impact factor: 3.507

10.  Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease.

Authors:  E Louis; R Louis; V Drion; V Bonnet; A Lamproye; M Radermecker; J Belaiche
Journal:  Allergy       Date:  1995-09       Impact factor: 13.146

View more
  3 in total

1.  Assessment of Occult Pulmonary Involvement in Ulcerative Colitis.

Authors:  Sudhir J Gupta; Vineet L Gupta; Harit G Kothari; Amol R Samarth; Nitin R Gaikwad; Sahil M Parmar
Journal:  Inflamm Intest Dis       Date:  2020-07-01

Review 2.  Association of sirtuins (SIRT1-7) with lung and intestinal diseases.

Authors:  Yuhan Chen; Di Zhou; Yuan Feng; Bingxin Li; Yong Cui; Gang Chen; Ning Li
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

3.  The Immune Change of the Lung and Bowel in an Ulcerative Colitis Rat Model and the Protective Effect of Sodium Houttuyfonate Combined With Matrine.

Authors:  Lulu Ni; Shan Jing; Li Zhu; Xue Yang; Xinyue Wang; Su Tu
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.